BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Oncologic Drugs Advisory Committee (ODAC) on March 15, 2024.

Aurora Spine Corporation today announced the issuance of its second United States Patent No: 11,850,162 entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for The World’s First DEXA Technology™ Patient-Matched Implant Technology.

Verrica Pharmaceuticals Inc. today announced that it has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc., a Canada corporation (“Dormer Labs”) requesting, among other relief, that the court enjoin Dormer Labs from marketing, selling, and distributing drugs containing cantharidin in the United States, as well as compensatory, statutory and punitive damages for Dormer Labs’ violations of the federal Lanham Act and Pennsylvania law.

Microbot Medical Inc., developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption application with the US Food and Drug Administration.

biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC).

MBX Biosciences, Inc. today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.

Jasper Therapeutics, Inc. today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.

Aclarion, Inc. announced that it has completed several recent financing transactions that have significantly reduced debt and increased available cash.

A clinical study to validate the beta thalassemia diagnostic capability of the Gazelle™ Hb Variant Test from Hemex Health, published in the journal Biosensors, showed that Gazelle correctly identified participating subjects with beta-thal major, beta-thal intermedia, and beta-thal trait with a combined accuracy of over 99% compared with the laboratory gold standard--high performance liquid chromatography (HPLC).

Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgenetic Alopecia (AGA).